`
`WIPO
`WORLD
`INTELLECTUAL PROPERTY
`ORGANIZATION
`
`
`DOCUMENT MADE AVAILABLE UNDER THE
`
`PATENT COOPERATION TREATY (PCT)
`international application number:
`PCTIU52013i‘046760
`
`international filing date:
`
`14 August 2018 (14.08.2018)
`
`Document type:
`
`Document details:
`
`Certified copyr of priority document
`
`Countrlefiice:
`Number:
`Filing date:
`
`US
`62I545,406
`14 August 2017 (14.03.2017)
`
`Date of receipt at the International Bureau:
`
`27 August 2018 (27.08.2018)
`
`Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rute
`17.1(a),(b) or (tn-bis)
`
`9.1.
`1.: =
`
`-:i’sc.-rnir (Iii-2 (Luvs-r r:c:-"--"q
`
`' Gr:--1r:-\.--. 2-2}. ESV.‘II?{."I;i-’"CI
`
`www.wipo.int
`NEUROCRINE 1004
`
`1
`
`1
`
`NEUROCRINE 1004
`
`

`

`I} 3' I'M: 1) STA! ES DEPAR”3‘?\I EST (J I? CO M M I'ZRE ‘1-3
`
`{Suited States Patent and 'l‘radumnrk Office
`
`August 26, 2018
`
`Patent and Trademark Office
`
`THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
`THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
`OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
`APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
`FILING DATE.
`
`APPLICATION NUMBER: 62/545,406
`FILING DATE: August 14, 20E 7
`RELATED PCT APPLICATION NUMBER: PCT/US] 8/46760
`
`THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY
`APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS
`CONVENTION, IS US62/545,406
`
`(.‘erIiiied by
`
`finder fiwrctm'y of (.‘nmmurcr
`for Intelleciual Proper!)-
`aud Director nnm- united States
`
`2
`
`

`

`Doc Code: TR.PROV
`
`Document Description: Provisional Cover Sheet (8816)
`
`F‘TDISBMS {11 418)
`Approved for use lhroogh {15(31 #2015. OMB 0651-0032
`U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reductionm OH 995. no persons are required to respond to a collection 01 information unless itdisplays a vaiid OMB control number
`
`Provisional Application for Patent Cover Sheet
`This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.530;)
`
`
`lnventor(s)
`Inventor 1
`
`Given Name
`Middle Name
`City
`Family Name
`
`
`
`
`
`
`. an Francisco
`OWERTON
`Z
`
`Inventor 2
`
`
`
`
`
`
`
`
`Given Name
`Middle Name
`Family Name
`City
`State
`Country i
`
`
`Ail In ventors Must Be Listed — Additional Inventor lnfcrmalion blocks may be
`Add
`
`generated within this form by selecting the Add button.
`
`Title of Invention
`
`Attorney Docket Number (if applicable)
`
`‘ ORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`E0535-709101
`
`l
`
`Correspondence Address
`
`Direct all correspondence to (select one]:
`
` © The address corresponding to Customer Number 0 Firm or Individual Name
`
`
`Customer Nu mber
`
`
`The invention was made by an agency of the United States Government or under a contract with an agency of the United
`States Govern merit.
`
`
`
`
`Yes, the invention was made by an agency of the United States Government. The U.S. Government agency name is:
`Yes, the invention was under a contract with an agency of the United States Government. The name of the U.S.
`Government agency and Government contract number are:
`
`
`
`EFS - Web1.0.1
`
`
`
`
`
`3
`
`

`

`Doc Code: TR.PROV
`
`Document Description: Provisional Cover Sheet (8816)
`
`F‘TDISBMEE {11-08)
`Approved for use through {1501 #2015. OMB 0651-0032
`U.S. Patent and Trademark Office: US. DEPARTMENT OF COMMERCE
`Under the Paperwork ReduclionAct of 1995. no persons are required to respond to a collection 01 information unless itdisplays a vatid OMB control number
`
`Entity Status
`Applicant asserts small entity status under 37 CFR 1.2? or applicant certifies micro entity status under 37 CFR 1.29
`
`
`
`0 .
`
`0 Applicant certifies micro entity status under 37 CFR 1.29. Applicant must attach torm PTOi’SEllr 15A or B or equivalent.
`
`
`Warning
`
`Petitionerfapplicant is cautioned to avoic.l submitting personal information in documents filed in a patent application that may
`contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card
`numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required
`by the USPTO to support a petition or an application.
`If this type of personal information is included in documents submitted
`to the USPTO, petitionerslapplicants should consider redacting such personal information from the documents before
`submitting them to USPTO. Petitionen’applicant is advised that the record of a patent application is available to the public
`alter publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(3) is made in the
`application) or issuance of a patent. Furthermore. the record from an abandoned application may also be available to the
`public if the application is referenced in a published application or an issued patent [see 37 CFR1.14). Checks and credit
`card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are
`not publiciy available.
`
`
`
`
`Signature
`
`Ptease see 37 CFR 1.4(d) for the form of the signature.
`
`
`Signatu re
`
`Celine Bonnefousir
`
`Date {YYYY—MM—DD)
`
`- o1 7.05.14
`
`First Name
`
`Last Name
`
`Registration Number
`{if appropriate)
`
`2375
`
`This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to
`file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection
`is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO.
`Time will varyr depending upon the individual case. Any comments on the amou'it of time you require to complete this form andior
`suggestions for reducing this burden, should be sent lathe Chiel Information Officer, US. Patent and Trademark Office, US Department
`of Commerce. PO. Box 1450, Alexandria, VA 2231371450. DO NOT SEND FEES 0R COMPLETED FORMS TO THIS ADDRESS. This
`form can only be used when in conjunction with EFS-Web. if this form is mailed to the USPTO, it may cause delays in handling
`the provisional application.
`
`
`
`EFS - Web1.0.1
`
`4
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of
`the attached form related to a patent application or paten. Accordingly. pursuant to the requirements of the Act. please be
`advised that : (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the
`information solicited is voluntary; and (3) the principal purpose for which the information is used by the US. Patent and
`Trademark Office is to process andfor examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process andfor examine your
`submission. which may result in termination ct proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`‘I.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information
`Act [5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the
`Department of Justice to determine whether disclosure of these records is required by the Freedom of Information
`Act.
`
`A record from this system of records may be disclosed, as a routine use. in the course of presenting evidence to
`a court, magistrate. or administrative tribunal. including disclosures to opposing counsel in the course of settlement
`negotiations
`A record in this system of records may be disclosed. as a routine use. to a Member of Congress submitting a
`request involving an individual, to whom the record pertains. when the individual has requested assistance from the
`Member with respect to the subject matter of the record.
`A record in this system of records may be disclosed. as a routine use. to a contractor of the Agency having need
`for the information in order to perform a contract. Recipients of information shall be required to comply with the
`requirements of the Privacy Act of 19?4, as amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed. as a routine use. to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed. as a routine use, t o a n other federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator. General Services.
`or hislher designee. during an inspection of records conducted by GSA as part of that agency's responsibility to
`recommend improvements in records management practices and programs. under authority of 44 U56. 2904 and
`2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this
`purpose. and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make
`determinations about individuals.
`A record from this system of records may be disclosed, as a routine use. to the public alter either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U_S.C. 151. Further. a record
`may be disclosed. subject to the limitations of 37 CFR 1.14. as a routine use. to the public it the record was filed in an
`appiication which became abandoned or in which the proceedings were terminated and which appiication is
`referenced by either a published application, an application open to public inspection or an
`issued patent.
`A record from this system of records may be disclosed, as a routine use. to a Federal. State. or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`5
`
`

`

`PTOIAWt-t (11-15]
`Approved for use through MBDQOW. OMB 055143032
`U.S. Patent and Trademark Cities; US. DEFAFt'lT-IENT OF COMMERCE
`Underme Fapenvom Reduction Actof1995. no persons are requrred to {es-pond to a collection of infotrnati-on unless it contains a valid OMB mntml number.
`
`
`50535—709101
`
`Attorney Docket Number
`
`
`Application Data Sheet 37 CFR 1.76
`
`Application Number
`
`
`CORTICOTROF’IN RELEASING FACTOR RECEPTOR ANTAGONISTS
`Title of Invention
`
`
`
`The application data sheet is part of the provisional or nonprovlsional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United Slates Patent and Trademark Office as outlined in 37 CFR 1.?5.
`This document may be completed electroniu'illy and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`
`document may be printed and induded in a paper filed application.
`
`
`Secrecy Order 37 CFR 5.2:
`
`1:! Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications thatfall under Secrecy Order may not be filed electronicatly.)
`
`Inventor Information:
`
`
`Inventor
`me’
`Legal Name
`
`
`
`Middle Name Family Name
`
` OWERTDN
`
`Residence information (Select One]
`a US Residency
`Non US Residency
`Acljve US Military Service
`
`any_ StatelProvince |. Country ornament_
`
`
`Mailing Address of Inventor:
`Add ress 1
`
`Add ress 2
`
`
`
`
`
` fll_I—I_I r
`Residence information (Select One]
`(9 US Residency
`Non US Residency
`Active US Military Service
`
`
`Mailing Address of Inventor:
`
`
`
`I" a Market Street
`I uite 74539
`I— stawProvinc-e
`Postal Code
`I:—_I 3
`All
`Inventors Must Be Listed - Additional
`Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`I A
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below-
`For further information see 37 GFR 1.33(a].
`
`EFS Web 2.2.12
`
`6
`
`

`

`
`
`Application Information:
`Title of the Invention
`
`
`
`Small Entity Status Claimed
`
`]:|
`
`
`
`
`
`
`
`
`Attorney Docket Number
`'00535-TDQ.101
`
`
`
`Application Type
`
`
`
`
`Subject Matter
`I—I
`
`
`
`Total Number or Drawing Sheets [if any} I_ Suggested Figure for Publication lifany} I
`
`Filing By Reference:
`
`Only complete this section when filing an application by reference under 35 U.S.C. Him and 37 CFR1.57(ai. Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate sectionlsi below (i.e.. ”Domestic Benefit/National Stage Inlormation" and ”Rareign Priority Information”).
`
`For the purposes of a filing date under 37 CFR 153(1)}. the description and any drawings of the present application are replaced by this
`
`reference to the previously filed application. subject to conditions and requirements of 37 CFR 1.57tal.
`_I
`Application number of the previously
`Filing date (YYYY—MM—DDJ
`Intellectual Property Authority or Country
`filed application
`
`
`
`
`Publication information:
`
`C Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`[ hereby request that the attached application not be published under
`Request Not 110 PUbliSi’l.
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached apptication has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months after filing.
`
`
`
`PTOIAW14(11-15]
`Approved for use through MBDQOW. OMB 1355143032
`U.S. Patent and Trademark Otfine; U‘S. DEFARTI'JENT OF COMMERCE
`Underthe Papenvork Reduction Actof 1995‘ no persons are required to respond lo a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`50535-709101
`
`CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`Title of Invention
`
`
`
`
`
` An Address is being provided for the correspondence lnfomation of this application.
`Customer Number
`
`I t 21971
`Ia alentdodret@wsgr.oom
`
`
`Email Address
`
`
`
`
`Remove Email
`
`
`
`
`
`Representative Information:
`
`in the application. Providing
`Representative information should be provided for all practitioners having a power of attorney:r
`this information in the Application Data Sheet does not constitute a power of attorney in the application {see 3? CFR 132].
`Either enter Customer Number or complete the Representative Name section below. if both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`
`
`
`
`
`I Customer Number
`
`US Patent Practitioner 0 Limited Recognition (37 CFR 11.9)
`
`Please Select One:
`Customer Number
`
`EFS Web 2 2.12
`
`7
`
`

`

`PTOIAW1-1fl1-15]
`Approved for use through MBDQOW. OMB 0651 £332
`U.S. Patent and Trademark 03109; US. DEFAFHT-IENT OF COMMERCE
`Underthe Papenvork Reduction Actof 1995. no persons are required to respond lo a collection of information unless it contains a valid OMB wntrol number.
`
`50535-709101
`
`Attorney Docket Number
`
`Application Number
`CORTI COTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`Ti‘tle of Invention
`
`
`Application Data Sheet 37 CFR 1.76
`
`
`Domestic Benefitmational Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C- 119(e). 120. 121, 365(c). or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120. and 37 CFR 1.73.
`When referring to the current application. please leave the “Application Number" field blank.
`
`
`Prior Application Number
`
`
`
`Application Number
`
`
`
`
`Prior Application Status
`
`Filing or 371(c) Date
`
`
`
`(YYYY—MM—DD)
`
`
`Additional Domestic BenefiUNationat Stage Data may be generated within this form
`by selecting the Add button.
`
`Continuity Type
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim pnonty to a foreign application. Prowding this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 155. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program {PDJIQ' the iniormation will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i){1) and (2]. Under the PBX program, applicant bears the uttimate
`responsibitity for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office. or a certified copy oi the foreign priority application is filed‘ within the time period specified in 3? CFR 1.55(g](13.
`
`Application Number
`Countryi
`Filing Date (YWY—MM-DD)
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Access Codei (if applicable)
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at anytime, a claim to a claimed invention that has an effective filing date on or after March
`D 16. 2013.
`NOTE: By providing this statement under 3? CFR 1.55 or 1.73, this application. with a filing date on or alter March
`
`16, 2013. wiil be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2 2.12
`
`8
`
`

`

`PTOIAW14(11-15]
`Approved for use through MBDIEOW. OMB 056143032
`U.S. Patent and Trademark Cities; US. DEPARTMENT OF COMMERCE
`
`Underthe Papenvom Reduction Actof 1995‘ no persons are required to respond lo a collection of information unless it contains a valid OMB ca'itrnl number.
`
`Attorney Docket Number
`50535-709101
`_
`Application Data Sheet 37 CFR 1.76
`
`—
`CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`Title of Invention
`
`
`.—
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IF) office access to the instant application-as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph B in subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below. applicant mustoptrout of the
`authorization by checking the corresponding box A or E or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP olfioe(s).
`Instead. Form PTOISBBQ or PTOISBIGQ must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign intellectual Property Office{s)
`
`A. Priority Document Exchange (PBX) - Unless box A in subsection 2 [opt-out of authorization) is checked. the
`undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO). the Japan Patent Office
`(JPO). the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of
`China (SIPO), the World Intellectual Property Organization {WIPO}, and any other foreign intellectual property offic-
`participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`and its related bibliographic data. (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data. and [3} the date of filing of this Authorization. See 37 CFR 1.14(h)
`(1)-
`
`B. Search Results from 3.1.5. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked.
`the undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property 0ffice(s)
`
`|:|
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`application-as-filed.
`If this box is checked, the USPTO will not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`
`:] application. Ifthis box is checked. the USPTO will not be providing the EPO with search results from the instant
`application.
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the
`application in accordance with 3? CFR 1.14.
`
`
`
`
`
`
`EFS Web 2 2.12
`
`9
`
`

`

`PTOIAWM (11-15]
`Approved for use through WWW. OMB 056143032
`U.S. Patent and Trademark 03109; US. DEFAFt'lT-IENT OF COMMERCE
`Underthe Papenvork Reduction Actof 1995‘ no persons are required to respond lo a oollec‘lion of information unless it contains a valid OMB ca'rtrnl number.
`
`Attorney Docket Number
`50535-709101
`_
`Application Data Sheet 37 CFR 1.76
`—
`Title of Invention
`CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONlSTS
`
`.—
`
`
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute tor compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`Applicant
`i]
`If the applicant is the inventor {or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed
`The information to be provided In this section is the name and address of the legal representative who is die applicant under 3? CFR
`1.43: or the name and address of the assignee. person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 3? CFR 1.46. if the applicant is an
`applicant under 37 CFR [46 {assignee person to whom the inventor is obligated to assrgn. or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are atso the applicant should be
`identified in this section.
`
`Joint Inventor
`Legal Representative under 35 U.S.C. 117
`a Assignee
`
`Person to whom the inventor is obligated to assign.
`Person M10 shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Name of the Deceased or Legally Incapacitated Inventor:
`
`If the Applicant is an Organization check here.
`
`E
`
`Mailing Address Information For Applicant:
`
`
`
`
`
`Address 1
`I 48 Market Street
`
`
`l~uite 74539
`
`
`
`StatelProvince
`
`
`Postal Code
`
`
`
`
` Email Address
`
`
`
`
`Additional Applicant Date may be generated within this form by selecting the Add button.
`
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 ofTitie
`37 of CFR to have an assignment recorded by the Office.
`
`
`EFS Web 2 2.12
`
`10
`
`10
`
`

`

`PTOIAWM (11-15]
`Approved for use through MBDQOW. OMB 0651 £332
`U.S. Patent and Trademark 03109; US. DEFAFHT-IENT OF COMMERCE
`
`Underthe Papenvork Reduction Actof 1995‘ no persons are required to respond lo a collection of information unless it contains a valid OMB «antral number.
`
`Application Data Sheet 37 CFR 1.76
`
`50535-709101
`
`Attorney Docket Number
`_
`.
`
`CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`Title of Invention
`
`
`j]
`Assignee
`Complete this section if assignee intonhalion, including non-applicant assignee information. is desrred to be included on the patent
`application publication. An assigneeapplicanl identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee—applicant. complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`I]
`
`
`
`I——I—
`
`
`I——I—
`
`
`
`
`
`
`
`
`
`
`Add rear. 1
`
`Email Address
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this term by
`selecting the Add button.
`
`Remove
`Signature:
`NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33tb). However, if this Application
`Data Sheet is submitted with the _IN_IIIA_I, filing of the application and either box A or B is not checked in
`subsection 2 of the “Authorization or Opt-Out of Authorization to Permit Access" section, then this form must
`also be signed in accordance with 37 CFR 1.14m).
`This Application Data Sheet must be signed by a patent practitioner it one or more oi the applicants is a juristic
`entity (e.g.. corporation or association). It the applicant is two or more joint inventors. this form must be signed by a
`patent practitioner, all joint inventors who are the applicant, or one or more joint inventor-applicants who have been given
`power of attorney (e.g.. see US PTO Form PTOIAW81) on behalf of all joint inventor-applicants.
`See 3? CFR 1.4{dj for the manner of making signatures and certifications.
`
`
`Signature
`Date [YYYY-MM-DD} 917-08-14
`
`
`
`
`
` First Name
`: onneto us
`
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`EFS Web 2 2.12
`
`11
`
`11
`
`

`

`PTOIAWH (11-15]
`Approved for use‘thrnugh WWW. OMB 0661M
`U.S. Patent and Trademark Olfioe; U5. DEFAFHT-IENT OF COMMERCE
`
`Underihe Papemm Reduction Aetof 1995. no persons are required to respond lo a oollec‘lion of information unifies it contains a valid OMB control number.
`
`Attorney Docket Number
`50535-709101
`_
`Application Data Sheet 37 CFR 1.76
`
`—
`CORTI CDTROPIN RELEASING FACTOR RECEPTOR ANTAGONlSTS
`Title of Invention
`
`
`.—
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO In process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to lake 23 minutes to complete, including gathering. preparing, and submilting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form andlor suggestions for reducing this burden. should be sent to the Chief Inion'nation Officer. U.S. Patent and
`Trademark Office. US. Department of Commerce. P.O. Box 1450, Alexandria. VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND To: Commissioner for Patents, P.o. Box 1450. Alexandria, VA 22313-1450.
`
`EFS Web 2 2.12
`
`12
`
`12
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 19?4 (P.L. 93-5 W} requires that you be given certain information in connection with your submission of the attached form related to a patent
`application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that (T) the general authority for the col Iection of this information
`is 35 usc. 2mm: (2} furnish! ng ofthe information solicited Is voiu ntary; and (3) the principal purpose for which the Information is used by the us. Patent and
`Trademark Oflice isto process andior examine yoursubmission related to a patent applicationor patent. Ifyou do not furnish the requested information, the US.
`Patent and Trademark Office may not be ableto process andfor examine your submission, which may resuit in termination of proceedings or abandonment of
`the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`1
`
`The informatiooon this form will betreated confidentially to the extent allowed under the Freedom of Information Act (5 U.5.C. 552) and the Privacy
`Act (5 U51: 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of
`Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, asa routine use, in thecourse of presenting evidence to a court, magistrate, or administrative
`tribunal, Including disclosures to opposing counsel In the course of settlement negotiations.
`
`Arecofli in this system of records may be disclosed, as a routine use, to a MemberofCongress submitting a request involving an individual,towl‘a}m
`the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform
`a contract. Recipients of information shall be required to comply with the requirements ofthe Privacy Act of 1974. as amended, pursuant to S U.S.C.
`552aiml.
`
`A record re lobed to an International Application tiled under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use,
`to the international Bureau ofthe World Intellectual Property Organiltion, pursuant to the Patent Coo perationTreaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agencyfor purposesot National Securityreview (35 U.5.C. 181)
`and for review pursuant to the Atomic Energy Act (42 U5.C. 21 Bicii
`
`A record lrom this system ofrecords may be disclosed, as a routine use, to the Adhinistrator. General Servic as or hisn’her designee, during an
`inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and
`programs. under authority of44 {ISL 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of
`records for this purpose, and any other relevant (ie, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about
`individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.5.CA
`122th) or issuance ofa patent pursuantto 35 USE. 151. Further, a record may be disclosed, subject to the limitations of 3? CFR i .14, as a routine use,
`to the public Ifthe record was filed In an application which became abandoned or In which the proceedings were terminated and which application ls
`re‘lerenced by either a published application, an application open to public inspections oran issued patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal. State, or local law enforcement agency, ifthe U5 PTO becomes
`aware of a violation or potential violation of law or regulation.
`
`
`
`
`
`
`EFS Web 2.2.12
`
`13
`
`13
`
`

`

`WSGR Docket No. [505357709101]
`
`PATENT APPLICATION
`
`CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`
`Invcntmfs}: Alexis HOWERTON
`548 Market Street. Suite 74589
`
`San Francisco, California 94105
`
`Hal GERBER.
`548 Markcl Street. Suite 74589
`San Francisco, California 94105
`
`Assigncc:
`
`Spruce Bioscicnccs, Inc.
`548 Markcl Street, Suite 74589
`San Francisco. California 94105
`
`Entity:
`
`Large business concern
`
`Wilson Sonsini Gooéricli 63’ Ros-Mi
`E'RCJP li‘fié?! (IE-J ‘. 1.
`'1}?! ii PG !E :81" {(3 N
`
`650 Page Mill Road
`Palo Altnt CA 94304
`(650) 493-9300 (Main)
`(650) 493—681 I (Facsimile)
`
`Filed Electronically on: August 14, 2017
`
`WSUR Docket No. 505353091!”
`
`14
`
`14
`
`

`

`CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
`
`BACKGROUND OF THE INVENTION
`
`[0001] Corticotropin releasing factor tCRF) is a 41 amino acid peptide that is the primary
`
`physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from